<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158184</url>
  </required_header>
  <id_info>
    <org_study_id>#4691</org_study_id>
    <secondary_id>R01DA016759-01</secondary_id>
    <nct_id>NCT00158184</nct_id>
  </id_info>
  <brief_title>Prescription Opioid Effects in Abusers Versus Non-Abusers</brief_title>
  <official_title>Prescription Opioid Effects in Drug and Non-drug Abusers - 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the abuse liability of oxycodone in individuals with,
      and without, a history of prescription opioid abuse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prescription opioid abuse is becoming an increasingly widespread and serious public health
      concern. The 2001 National Household Survey on Drug Abuse report revealed that the number of
      first-time users of prescription opioid medications for non-medical reasons reached 2 million
      in the year 2000, a number that has quintupled since 1984. Despite this trend, little
      experimental research has been directed towards understanding who may be abusing these
      medications, and under what conditions. The study will examine the reinforcing, subjective,
      performance, and physiological effects of oxycodone. Because it is not clear who is abusing
      prescription opioids, the medication effects will be compared in drug abusers and non-drug
      abusers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breakpoint</measure>
    <time_frame>Measured at 0, 60, 120, 180 and 240 minutes following administration of each oral oxycodone dose (0 , 15, 30 mg). Results presented as mean of the session</time_frame>
    <description>Maximum number of finger presses on a computer mouse completed. The &quot;Breakpoint&quot; is the amount of work (clicks on a mouse) participants were willing to do in order to received the dose of drug under investigation. This is a commonly used indicator of a drugs value and abuse liability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Liking</measure>
    <time_frame>Highest rating obtained following adminstration of each of the 3 test doses.</time_frame>
    <description>Subjective rating of drug &quot;Liking&quot; on a scale of 0 to 100. Greater numbers indicate greater subjective report of &quot;Liking.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Rx Opioid Abusers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rx Opioid Non-Abusers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone 15 mg</intervention_name>
    <description>15 mg/70 kg oxycodone administered once per day, orally.</description>
    <arm_group_label>Rx Opioid Abusers</arm_group_label>
    <arm_group_label>Rx Opioid Non-Abusers</arm_group_label>
    <other_name>immediate-release oxycodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone 30 mg</intervention_name>
    <description>30 mg/70 kg oxycodone administered once per day, orally.</description>
    <arm_group_label>Rx Opioid Abusers</arm_group_label>
    <arm_group_label>Rx Opioid Non-Abusers</arm_group_label>
    <other_name>immediate-release oxycodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0 mg</intervention_name>
    <description>0 mg placebo dose administered once a day, orally.</description>
    <arm_group_label>Rx Opioid Abusers</arm_group_label>
    <arm_group_label>Rx Opioid Non-Abusers</arm_group_label>
    <other_name>0 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good physical health

          -  Women reporting regular menstrual cycles lasting between 24 to 35 days

          -  Able to perform study procedures

          -  Normal body weight

          -  Use of opioids for medical purposes (cough, pain, or diarrhea) or recreational
             purposes at least twice in lifetime with no serious adverse effects

          -  Current opioid abuse, but not opioid dependence (drug abusers only)

        Exclusion Criteria:

          -  On parole or probation

          -  Recently convicted of a crime of violence

          -  History of significant violent behavior

          -  Current Axis I psychopathology

          -  Significant Axis II disorder

          -  Pregnancy

          -  Women who have irregular menstrual cycles, or who are dysmenorrheic, amenorrheic, or
             menopausal

          -  Women who have been pregnant or breastfeeding within the past 6 months

          -  Women who have had a miscarriage or abortion within the past 6 months

          -  Women who meet DSM-IV criteria for premenstrual dysphoric disorder

          -  Women who report suffering from moderate to severe premenstrual symptoms

          -  Women seeking treatment for premenstrual problems

          -  Taking prescription or over-the-counter psychotropic medication

          -  History of chronic pain, or routinely uses over-the-counter analgesics (more than 4
             days per month)

          -  Blood pressure greater than 150/90 mm Hg

          -  Reports of sensitivity, allergy, or contraindication to opioids

          -  Non-drug abusers:

               1. Current or lifetime history of substance abuse or dependence according to DSM-IV
                  criteria (those requiring detoxification)

               2. Consumes more than 500 mg caffeine daily

               3. Seeking treatment for substance use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Comer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, Houser J. Abuse liability of oxycodone as a function of pain and drug use history. Drug Alcohol Depend. 2010 Jun 1;109(1-3):130-8. doi: 10.1016/j.drugalcdep.2009.12.018. Epub 2010 Jan 15.</citation>
    <PMID>20079977</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>June 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opiate</keyword>
  <keyword>Opioid</keyword>
  <keyword>Abuse Liability</keyword>
  <keyword>Abuse Potential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rx Opioid Abusers</title>
          <description>The Abuse potential 3 doses of oral oxycodone (0, 15, 30 mg) were tested among a group of recreational prescription opioid (Rx) users.</description>
        </group>
        <group group_id="P2">
          <title>Rx Opioid Non-Abusers</title>
          <description>The Abuse potential 3 doses of oral oxycodone (0, 15, 30 mg) were tested among a group of participants with no history of opioid abuse.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>personal issues</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>failed for follow unit/study rules</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rx Opioid Abusers</title>
          <description>Prescription Opioids users with abusive patterns of use.</description>
        </group>
        <group group_id="B2">
          <title>Rx Opioid Medical Users</title>
          <description>Prescription Opioids users without abusive patterns of use.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="8"/>
                    <measurement group_id="B2" value="28" spread="6"/>
                    <measurement group_id="B3" value="30" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Breakpoint</title>
        <description>Maximum number of finger presses on a computer mouse completed. The &quot;Breakpoint&quot; is the amount of work (clicks on a mouse) participants were willing to do in order to received the dose of drug under investigation. This is a commonly used indicator of a drugs value and abuse liability.</description>
        <time_frame>Measured at 0, 60, 120, 180 and 240 minutes following administration of each oral oxycodone dose (0 , 15, 30 mg). Results presented as mean of the session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rx Opioid Abusers</title>
            <description>Recreational prescription opioid users.</description>
          </group>
          <group group_id="O2">
            <title>Rx Opioid Non-Abusers</title>
            <description>Medical prescription opioid users.</description>
          </group>
        </group_list>
        <measure>
          <title>Breakpoint</title>
          <description>Maximum number of finger presses on a computer mouse completed. The &quot;Breakpoint&quot; is the amount of work (clicks on a mouse) participants were willing to do in order to received the dose of drug under investigation. This is a commonly used indicator of a drugs value and abuse liability.</description>
          <units>Mouse Clicks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo: 0 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="20"/>
                    <measurement group_id="O2" value="400" spread="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: 15mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1400" spread="400"/>
                    <measurement group_id="O2" value="850" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: 30mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="350"/>
                    <measurement group_id="O2" value="900" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Liking</title>
        <description>Subjective rating of drug &quot;Liking&quot; on a scale of 0 to 100. Greater numbers indicate greater subjective report of &quot;Liking.&quot;</description>
        <time_frame>Highest rating obtained following adminstration of each of the 3 test doses.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rx Opioid Abusers</title>
            <description>Recreation users</description>
          </group>
          <group group_id="O2">
            <title>Rx Opioid Non-Abusers</title>
            <description>Medical users</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking</title>
          <description>Subjective rating of drug &quot;Liking&quot; on a scale of 0 to 100. Greater numbers indicate greater subjective report of &quot;Liking.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo: 0 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="5"/>
                    <measurement group_id="O2" value="21" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: 15 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="7"/>
                    <measurement group_id="O2" value="53" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: 30 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="8"/>
                    <measurement group_id="O2" value="40" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Averse events were assessed daily from the date of admission until the date of discharge. Participants also returned for a 30-Day follow-up after being discharged, during which adverse events were assessed.</time_frame>
      <desc>Adverse events are classified as serious or non-serious.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rx Opioid Abusers</title>
        </group>
        <group group_id="E2">
          <title>Rx Opioid Non-Abusers</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Occurred after admission but prior to oral oxycodone being given.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sandra D. Comer</name_or_title>
      <organization>Substance Use Research Center</organization>
      <phone>212-543-5981</phone>
      <email>sdc10@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

